Neonatal respiratory distress syndrome primary prevention

Revision as of 20:11, 13 February 2013 by Prashanthsaddala (talk | contribs)
Jump to navigation Jump to search

Neonatal respiratory distress syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neonatal respiratory distress syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neonatal respiratory distress syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neonatal respiratory distress syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neonatal respiratory distress syndrome primary prevention

CDC on Neonatal respiratory distress syndrome primary prevention

Neonatal respiratory distress syndrome primary prevention in the news

Blogs on Neonatal respiratory distress syndrome primary prevention

Directions to Hospitals Treating Neonatal respiratory distress syndrome

Risk calculators and risk factors for Neonatal respiratory distress syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Primary Prevention

Most cases of hyaline membrane disease can be ameliorated or prevented if mothers who are about to deliver prematurely can be given one of a group of hormones glucocorticoids. This speeds the production of surfactant. For very premature deliveries, a glucocorticoid is given without testing the fetal lung maturity. In pregnancies of greater than 30 weeks, the fetal lung maturity may be tested by sampling the amount of surfactant in the amniotic fluid, obtained by inserting a needle through the mother's abdomen and uterus. The 'maturity level' is expressed as the lecithin-sphingomyelin (or "L/S") ratio. If this ratio is less than 2, the fetal lungs may be surfactant deficient, and a glucocorticoid is given.

References

Template:WH Template:WS